Regeneron Pharmaceuticals Inc (REGN)

Pretax margin

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Earnings before tax but after interest (EBT) (ttm) US$ in thousands 4,199,300 4,376,400 4,775,400 4,655,700 4,858,800 6,037,500 6,344,300 9,133,900 9,325,800 8,047,000 7,228,700 4,394,800 3,810,400 3,475,600 3,245,800 2,551,600 2,429,100 2,215,500 2,082,900 2,514,300
Revenue (ttm) US$ in thousands 13,044,200 13,025,200 12,601,200 12,306,100 12,113,500 13,654,100 14,171,800 16,451,800 16,014,400 13,499,700 12,328,800 9,147,000 8,455,000 8,201,600 7,974,500 7,957,900 7,839,900 7,598,200 7,213,600 6,889,000
Pretax margin 32.19% 33.60% 37.90% 37.83% 40.11% 44.22% 44.77% 55.52% 58.23% 59.61% 58.63% 48.05% 45.07% 42.38% 40.70% 32.06% 30.98% 29.16% 28.87% 36.50%

December 31, 2023 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $4,199,300K ÷ $13,044,200K
= 32.19%

Regeneron Pharmaceuticals, Inc. has shown a gradual decline in its pretax margin over the past eight quarters. The pretax margin was highest in Q1 2022 at 55.33% but has since experienced a downward trend, reaching its lowest value of 32.01% in Q4 2023. This decrease may indicate inefficiencies in cost management or a decrease in revenue relative to expenses. The declining pretax margin suggests that Regeneron Pharmaceuticals, Inc. may need to focus on improving operational efficiency and cost control measures to enhance profitability.


Peer comparison

Dec 31, 2023